Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Abstract: A reagent of the formula R1R2N—ZnY LiY??(I) wherein R1 and R2 are independently, selected from H, aryl or heteroaryl, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or silyl derivatives thereof; and R1 and R2 together form part of a cyclic or polymeric structure; R1 and/or R2 is not H; Y is F, Cl, Br, I, CN, SCN, NCO or HalOn, wherein n=3 or 4 and Hal is Cl, Br or I; NO3; BF4; PF6; H; a carboxylate of formula R5CO2; an alcoholate of formula OR5; a thiolate of formula SR5; R5P(O)O2; or SCOR5; or SCSR5; OnSR5; wherein n=2 or 3; or NOn, wherein n=2 or 3; and a derivative thereof; wherein R5 is an aryl or heteroaryl, linear, branched or cyclic, alkyl, alkenyl, alkynyl, or derivatives thereof, or H; or as adduct with a solvent; and preparation and use thereof.

Abstract: Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided.

Abstract: This invention relates to methods for treating, preventing, or reversing brain disease or damage produced by chronic alcohol intake by administering a peroxisome proliferator activated receptor (PPAR) agonist.

Abstract: Provided herein are quinazoline compounds of formula (I): The compounds are useful for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Abstract: Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

Abstract: Described herein are organic photovoltaic (OPV) cells using gold complex(es) with as chemical structure of Structure I as active material: wherein, wherein R1-R15 are independently hydrogen, halogen, hydroxyl, an unsubstituted alkyl, a substituted alkyl, cycloalkyl, an unsubstituted aryl, a substituted aryl, acyl, alkoxy, acyloxy, amino, alkylamino, nitro, acylamino, aralkyl, cyano, carboxyl, thio, styryl, aminocarbonyl, carbamoyl, aryloxycarbonyl, phenoxycarbonyl, hydroxyalkyl, or an alkoxycarbonyl group. The OPV cell can be fabricated by thermal deposition or solution process such as spin coat and printing.

Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, L, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: Compounds of formula (I) and their uses as inhibitors of tyrosine kinases, in particular Met kinase, and their employment in methods for the treatment of tumors.

Abstract: Provided as a novel substance is a long-lifetime organometallic iridium complex emitting yellow light with high emission efficiency. The organometallic iridium complex is represented by General Formula (G1) and has a structure in which a phenyl group whose 2-position and 6-position are each substituted by an alkyl group is bonded to the 4-position of pyrimidine. In General Formula (G1), R1 and R2 each independently represent a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms.

Abstract: The present invention discloses a series of alkylamino BODIPY dyes, methods for preparing a library of alkyl-amino BODIPY dyes via solid-phase synthesis, and the use of the alkyl-amino BODIPY dyes as fluorescent sensors for protein detection, cell imaging and cytometry applications, and staining of certain cell line.

Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

Abstract: Heteroaryl-aryl compounds such as compounds represented by the Formula: HT-[Ph1]r-Py-Het-ET may be used in electronic devices such as organic light-emitting devices. For example, the compounds may be used as an emissive material in an emissive layer.

Abstract: The present invention provides a crystalline form of HPPH (2-((1?-n-hexyloxy)ethyl)-2-divinyl-pyropheophorbide-a): The crystalline form can be characterized by an X-ray powder diffraction (XRD) pattern and differential scanning calorimeter (DSC) pattern. The present invention also provides a method for preparing the crystalline form of HPPH.

Abstract: An object is to provide a novel organometallic complex capable of emitting phosphorescence, an organometallic complex which exhibits deep red emission, and a light-emitting element which provides deep red emission. Provided is an organometallic complex having a structure represented by the following General Formula (G1). In the formula, R1, R2, R3, R4, R5, R6, R7, R8, and R9 represent substituents, and M is a central metal and represents either a Group 9 element or a Group 10 element.

Abstract: Metallocorrole complexes of third row transition metals (see Formula I below) may be used as therapeutic agents, catalysts, components of oxygen detectors, and components of light emitting diodes. In particular, metallocorrole complexes of third row transition metals may be used as improved photosenitizers in photodynamic therapy; as improved catalysts in aziridination, epoxidation, and water splitting reactions; as improved in vivo imaging agents; and as improved components in the emissive layer of OLEDs. Due to their strongly sigma-donating nature, corroles are able to stabilize third row transition metals in high oxidation states. Third row transition metals are significantly more electropositive than their first and second row counterparts and may therefore act as improved catalysts.

Abstract: The present disclosure provides purified pharmaceutical preparations comprising oxidized SkQ1, wherein no individual impurity exceeds 1.5%, the total impurity content of the preparation does not exceed 4.

Abstract: Process for preparing compounds of the diaminophenothiazinium type of formula (II) below. The products have a high degree of purity and are useful for the preparation of medicaments. In which the R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 groups having the same definition as in formula (I), and R representing a group chosen from: a phenyl or benzyl group, optionally substituted with one or more functions chosen from: a C1-C4 alkyl, a halogen atom, a C1-C4 haloalkyl and a nitro group, a linear, branched or cyclic C1-C8 alkyl group, a C1-C8 alkylamino group, a C1-C8 alkoxy group, a phenyloxy or benzyloxy group optionally substituted on the aromatic nucleus with one or more functions chosen from: a C1-C4 alkyl, a halogen atom, a C1-C4 haloalkyl and a nitro group, Z representing an atom chosen from O and S.